Harnessing systematic protein-ligand interaction fingerprints for drug discovery

18 July 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Determining protein-ligand interaction characteristics and mechanisms is critical in the drug discovery process. Here we review recent progress and successful applications of a systematic protein-ligand interaction fingerprint (IFP) approach for investigating proteome-wide protein-ligand interactions for drug development. Specifically, we review the use of this IFP approach for revealing polypharmacology across the whole kinome, predicting promising targets from which to design allosteric inhibitors and covalent kinase inhibitors, uncovering the binding mechanisms of drugs of interest, and demonstrating resistant mechanisms of specific drugs. Together, we demonstrate that the IFP strategy is efficient and practical for drug design research and development in the current era of big data.

Keywords

Interaction fingerprints
proteome-wide drug discovery
mechanism of drug resistance
antivirus drug discovery
structural systems biology
polypharmacology
allosteric inhibitors
covalent inhibitors

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.